Evotec OAI to Provide Process Validation for AnorMED Inc. Phase III Compound, AMD 3100
Evotec OAI AG announced that AnorMED Inc has selected Evotec OAI to support AnorMED with the chemical development of its candidate AMD 3100, currently under evaluation in the clinic in stem cell mobilisation for stem cell transplantation in cancer patients. Using its integrated chemical and pharmaceutical development platform, EVOdevelop(TM), Evotec OAI will complete the full validation of the process to AMD 3100, including process research and development, analytical work and cGMP manufacturing, and will be responsible for producing the relevant CMC documentation for subsequent dossier filing.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
List_of_health_topics:_S-Sc
Topfreedom
Category:Genes_on_chromosome_11

These microscopic fish are 3-D-printed to do more than swim
Polycythemia
Bowen's_Kale
Southern_blot
Hip_replacement_(animal)
Cytochrome_P450
Echinacea
New nanoscopic tools to study ligand-binding of receptors
